Proxy Materials

Cadrenal Therapeutics, Inc. Filed 2023-08-31 Acc 0001213900-23-072829

Documents 1

2024-06-12 DEFA14A Proxy Materials
2023-09-06 4 CEO and Chairman bought 40,000 shares at an average $0.90 ($36,188)
2023-09-05 4 CEO and Chairman bought 70,000 shares at an average $0.91 ($63,945)
2023-08-31 DEFA14A Proxy Materials
2023-08-31 DEFA14A Proxy Materials
2023-08-28 ARS Annual Report to Security Holders
2023-08-28 DEF 14A Proxy Statement

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

Loading ea184536-defa14a_cadrenal.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…